Cytogen (US) signs OncoScint partners:
This article was originally published in Clinica
Executive Summary
Cytogen (US) has signed letters of intent with CIS bio international (France) and Faulding (Canada) to market the OncoScint CR/OV imaging agent for detecting colorectal and ovarian cancers. CIS bio will distribute OncoScint in Europe and countries excluding North America, while Faulding is to distribute the agent in Canada. OncoScint is already marketed in the US by Cytogen's nuclear oncology department and has marketing approval in 13 European countries. It was previously marketed in Europe by EuroCetus, which was acquired by Chiron.